IP Library Granted Patent US 10,391,074
Granted Patent B2
US 10,391,074 · App. 14/098,633 · Granted Aug 27, 2019

Topical preparation for pain relief

Inventor: Michael Harvey Greenspan (Dacula, GA)
Assignee: Sambria Pharmaceuticals, LLC
A61K31/196A61K9/0014A61K31/08A61K31/10A61K31/167A61K31/245A61K31/573A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,391,074
App. No.
14/098,633
Granted
Aug 27, 2019
Kind
B2
Abstract

A composition for pain relief including synergistically effective amounts of an amino benzoate local anesthetic, methylsulfonylmethane (MSM), and ethoxydiglycol. A method of treating pain, by applying the composition to skin in an area of pain, and blocking nerve signals. A method of improving range of motion in an individual, by applying the composition to skin, relieving pain, and allowing the individual to have an improved range of motion at an area of pain.

Claims (23)

1. A method of reducing a sensation of pain in a subject, comprising:

applying topically directly to skin of the subject over an area of pain a therapeutic amount of a composition comprising

(a) lidocaine in an amount of about 1% to about 20%; and

(b) a penetration enhancer comprising a penetration-enhancing amount of a methylsulfonylmethane (MSM) component, and an ethoxydiglycol component, wherein the amount of the MSM component is about 1% to about 10%, and the amount of the ethoxydiglycol component is about 0.10% to about 5%,

wherein the composition is effective

(i) to deeply penetrate the skin of the subject,

(ii) to remain in the skin and block nerve signals affecting sensation of pain, and

(iii) to provide pain relief.

2. The method of claim 1 , wherein the pain is caused by a condition selected from the group consisting of a tear, tendonosis, supraspinatus acute tendonitis, chronic tendonitis, rotator cuff disease, neck and low back pain, herpes zoster, insect bites and stings, neuropathy, and migraine headaches.

3. The method of claim 1 , wherein the pain is caused by insect bites and stings, the composition further includes a therapeutic selected from the group consisting of cortisone and hydrocortisone, and the therapeutic amount is effective to provide an anti-inflammatory effect.

4. The method of claim 1 , wherein the pain is caused by migraine headaches, the composition further includes a therapeutic selected from the group consisting of a vasoconstrictor, an anti-inflammatory agent, and combinations thereof, and the therapeutic amount is effective to provide an anti-inflammatory effect.

5. The method of claim 1 , wherein the pain is caused by migraine headaches and the therapeutic effect further includes relaxing muscles that otherwise constrict around vessels blocking circulation and around nerves being impinged.

6. The method of claim 1 , wherein the administering is at multiple sites of the body.

7. The method of claim 1 , further including administering an anti-pain and anti-inflammatory agent selected from the group consisting of acetaminophen, aspirin, diflunisal, salsalate, indomethacin, ketorolac, sulindac, etodolac, diclofenac, nabumetone, ibuprofen, naproxen, flurbiprofen, ketoprofen, oxaprozin, fenoprofen, loxoprofen, meclofenamic acid, mefenamic acid, flufenamic acid, tolfenamic acid, piroxicam, meloxicam, tenoxicam, droxicam, lornoxicam, isoxicam, tolmetin, celecoxib, rofecoxib, valdecoxib, parecoxib, lumiracoxib, etoricoxib, firocoxib, steroids, and lidocaine.

8. A method of improving range of motion in an individual, including applying topically directly to the skin of the individual over an area of pain a therapeutic amount of a composition comprising

(a) lidocaine in an amount of about 1% to about 20%, and

(b) a penetration enhancer comprising a penetration-enhancing amount of a methylsulfonylmethane (MSM) component and a ethoxydiglycol component, wherein the amount of the MSM component is about 1% to about 10%, and the amount of the ethoxydiglycol component is about 0.10% to about 5%;

wherein the composition is effective

(i) to deeply penetrate the skin of the subject,

(ii) to remain in the skin of the subject and block nerve signals affecting sensation of pain; and

(iii) to improve range of motion at the area of pain by providing pain relief in the area of pain.

9. The method of claim 8 , further including administering an anti-pain and anti-inflammatory agent selected from the group consisting of acetaminophen, aspirin, diflunisal, salsalate, indomethacin, ketorolac, sulindac, etodolac, diclofenac, nabumetone, ibuprofen, naproxen, flurbiprofen, ketoprofen, oxaprozin, fenoprofen, loxoprofen, meclofenamic acid, mefenamic acid, flufenamicacid, tolfenamic acid, piroxicam, meloxicam, tenoxicam, droxicam, lornoxicam, isoxicam, tolmetin, celecoxib, rofecoxib, valdecoxib, parecoxib, lumiracoxib, etoricoxib, firocoxib, steroids, and lidocaine.

10. The method of claim 1 , wherein the lidocaine is present in an amount of about 4% to about 10%.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 30, 2021
From: SAMBRIA PHARMACEUTICALS, LLC
To: SBG MEDICAL TECHNOLOGIES, INC.
Reel/Frame 057676/0770 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 28, 2016
From: GREENSPAN, MICHAEL HARVEY
To: SAMBRIA PHARMACEUTICALS, LLC
Reel/Frame 038115/0994 →
Continuity (3)
Provisional Application 61765115 · Feb 15, 2013
Provisional Application 61734748 · Dec 7, 2012
Related Publication 20140163105A1 · Jun 12, 2014